Patent

I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail in an envelope addressed to: Box Patent Application, Commissioner For Patents, Washington, D.C. 20231 on this 23rd day of January, 2002.

By _____

(Signature of person mailing)

Janice M. Denison

_____

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **Lee Harland**   :

APPLICATION NO.:   **To be assigned**   :   Examiner: **To be assigned**

FILING DATE: **Herewith**   :   Group Art Unit: **To be assigned**

TITLE: **Novel Polypeptide**   :

Box Patent Application
Commissioner for Patents
Washington, D.C. 20231

STATEMENT REGARDING SUBMISSION
OF SEQUENCE LISTING UNDER 37 C.F.R. §1.821(f)

I hereby state that the information recorded in computer readable form is identical to the written sequence listing.

Respectfully submitted,

Date: 1/23/2002

Gabriel L. Kleiman
Attorney for Applicant(s)
Reg. No. 40,681

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0041

EXPRESS MAIL NO. EL912062320US

OIPE

CRF Problem Report

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: _10/055,106_
Filing Date: _1/23/2002_
Date Processed by STIC: _2/13/2002_

STIC Contact: **Mark Spencer, 703-308-4212**

Nature of Problem:

The CRF (was):

____ (circle one) Damaged or Unreadable (for Unreadable, see attached)
____ Blank (no files on CRF) (see attached)
____ Empty file (filename present, but no bytes in file) (see attached)
____ Virus-infected. Virus name: _____ The STIC will not process the CRF.
____ Not saved in ASCII text
____ Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should **only** be the Sequence Listing.
_✓_ Did not contain a Sequence Listing. (see attached sample)
____ Other: _____

PLEASE USE THE CHECKER VERSION 3.1 PROGRAM TO REDUCE ERRORS.
SEE BELOW FOR ADDRESS:
http:/www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.
Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.
Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. **EFS-Bio** (<http://www.uspto.gov/ebc/efs/downloads/documents.htm> , **EFS Submission User Manual** - ePAVE)
2. **U.S. Postal Service:** U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. **Hand Carry directly to:**
    U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
        Or
    U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. **Federal Express, United Parcel Service , or other delivery service to:** U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

OIPE

0590
4/25

CRF Problem Report

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: ___10/055,106 A___
Filing Date: ___01/23/2002___
Date Processed by STIC: ___4/22/02___

STIC Contact: **Mark Spencer, 703-308-4212**

Nature of Problem:

The CRF (was):

____ (circle one) Damaged or Unreadable (for Unreadable, see attached)
____ Blank (no files on CRF) (see attached)
____ Empty file (filename present, but no bytes in file) (see attached)
____ Virus-infected. Virus name: _____ The STIC will not process the CRF.
____ Not saved in ASCII text
____ Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should **only** be the Sequence Listing.
__✓__ Did not contain a Sequence Listing. (see attached sample)
____ Other: _____

PLEASE USE THE CHECKER VERSION 3.1 PROGRAM TO REDUCE ERRORS.
SEE BELOW FOR ADDRESS:
    http:/www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<**http://www.uspto.gov/ebc/efs/downloads/documents.htm**> , **EFS Submission User Manual** - ePAVE)
2. **U.S. Postal Service:** U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. **Hand Carry directly to:**
    U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
        Or
    U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. **Federal Express, United Parcel Service , or other delivery service to:** U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

$05.9c$
$07/0$

OIPE

CRF Problem Report

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: ___10/055,106B___
Filing Date: ___01 23 2002___
Date Processed by STIC: ___7 10 02___

STIC Contact: **Mark Spencer, 703-308-4212**

Nature of Problem:

The CRF (was):

✓ (circle one) (Damaged) or Unreadable (for Unreadable, see attached)
____ Blank (no files on CRF) (see attached)
____ Empty file (filename present, but no bytes in file) (see attached)
____ Virus-infected. Virus name: _____ The STIC will not process the CRF.
____ Not saved in ASCII text
____ Sequence Listing was embedded in the file. According to Sequence Rules,
        submitted file should **only** be the Sequence Listing.
____ Did not contain a Sequence Listing. (see attached sample)
____ Other:

**PLEASE USE THE CHECKER VERSION 3.1 PROGRAM TO REDUCE ERRORS.
SEE BELOW FOR ADDRESS:**
        http:/www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.
Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.
Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm> , EFS Submission
    User Manual - ePAVE)
2. **U.S. Postal Service:** U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. **Hand Carry directly to:**
    U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name,
    Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
                Or
    U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,
    2011 South Clark Place, Arlington, VA 22202
4. **Federal Express, United Parcel Service , or other delivery service to:** U.S. Patent and Trademark Office,
    Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

Sample page from 2 of 2 files

1) Major formatting error. If PatentIn. Software was used, please contact Robert Wat at 703-306-4119 or 703-308-4212 for assistance.

2) Note: please submit only 1 file!

See sample sequence listing attached!

```
Organization Applicant
----------------------
      Street :
      City :
      State :                  } delete
      Country :
      PostalCode :
      PhoneNumber :
      FaxNumber :
      EmailAddress :
<110> OrganizationName : Pfizer Inc.

Individual Applicant
--------------------
      Street :
      City :
      State :
      Country :                } delete
      PostalCode :
      PhoneNumber :
      FaxNumber :
      EmailAddress :
<110> LastName : Harland
<110> FirstName : Lee
<110> MiddleInitial :
<110> Suffix :

Application Project   ]— delete
-------------------
<120> Title : Novel Polypeptide
<130> AppFileReference : PC10970AGLK
<140> CurrentAppNumber :
<141> CurrentFilingDate : ____-__-__

Earlier Applications  } delete
-------------------
<150> PriorAppNumber : GB0101739.1
<151> PriorFilingDate : 2001-01-23

Earlier Applications  } delete
-------------------
<150> PriorAppNumber : US 60/267,341
<151> PriorFilingDate : 2001-02-08

Sequence
--------
<213> OrganismName : Homo sapiens
<400> PreSequenceString :
atgcctggcc acaatacctc caggaattcc tcttgcgatc ctatagtgac accccactta      60
atcagcctct acttcatagt gcttattggc gggctggtgg gtgtcatttc cattcttttc     120
ctcctggtga aaatgaacac ccggtcagtg accaccatgg cggtcattaa cttggtggtg     180
```

`CProjectData````łNovel Polypeptide ÿÿ´```CProject````ÿÿ´`
PC10970AGLK`
____-__-__```^H:~```ÿÿ´`

<110>   Smith, John; Smithgene Inc.

<120>   Example of a Sequence Listing

<130>   01-00001

<140>   PCT/EP98/00001
<141>   1998-12-31

<150>   US 08/999,999
<151>   1997-10-15

<160>   4

<170>   PatentIn version 2.0

<210>   1
<211>   389
<212>   DNA
<213>   Paramecium sp.

<220>
<221>   CDS
<222>   (279)...(389)

<300>
<301>   Doe, Richard
<302>   Isolation and Characterization of a Gene Encoding a
          Protease from Paramecium sp.
<303>   Journal of Genes
<304>   1
<305>   4
<306>   1-7
<307>   1988-06-31
<308>   123456
<309>   1988-06-31

<400>   1
agctgtagtc   attcctgtgt   cctcttctct   ctgggcttct   caccctgcta   atcagatctc   60

agggagagtg   tcttgaccct   cctctgcctt   tgcagcttca   caggcaggca   ggcaggcagc   120

tgatgtggca   attgctggca   gtgccacagg   cttttcagcc   aggcttaggg   tgggttccgc   180

cgcggcgcgg   cggcccctct   cgcgctcctc   tcgcgcctct   ctctcgctct   cctctcgctc   240

Appendix 3, page 2

ggacctgatt	aggtgagcag	gaggaggggg	cagttagc		atg	gtt	tca	atg	ttc	agc	296
					Met	Val	Ser	Met	Phe	Ser	
					1				5		

ttg	tct	ttc	aaa	tgg	cct	gga	ttt	tgt	ttg	ttt	gtt	tgt	ttg	ttc	caa	344
Leu	Ser	Phe	Lys	Trp	Pro	Gly	Phe	Cys	Leu	Phe	Val	Cys	Leu	Phe	Gln	
			10					15					20			

tgt	ccc	aaa	gtc	ctc	ccc	tgt	cac	tca	tca	ctg	cag	ccg	aat	ctt	389
Cys	Pro	Lys	Val	Leu	Pro	Cys	His	Ser	Ser	Leu	Gln	Pro	Asn	Leu	
		25					30					35			

<210> 2
<211> 37
<212> PRT
<213> Paramecium sp.

<400> 2

Met	Val	Ser	Met	Phe	Ser	Leu	Ser	Phe	Lys	Trp	Pro	Gly	Phe	Cys	Leu
1				5					10					15	

Phe	Val	Cys	Leu	Phe	Gln	Cys	Pro	Lys	Val	Leu	Pro	Cys	His	Ser	Ser
			20					25					30		

Leu	Gln	Pro	Asn	Leu
		35		

<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ.

<400> 3

Met	Val	Asn	Leu	Glu	Pro	Met	His	Thr	Glu	Ile
1				5					10	

<210> 4
<400> 4
000

[Annex VIII follows]

identifiers and their accompanying information as shown in the following table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials	M
<120>	Title of Invention		M
<130>	File Reference	Personal file reference	M, when filed prior to assignment of appl. number
<140>	Current Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOs	Count includes total number of SEQ ID NOs	M
<170>	Software	Name of software used to create the Sequence Listing	O
<210>	SEQ ID NO:#:	Response shall be an integer representing the SEQ ID NO shown	M
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	M

<212>	Type	Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/RNA molecule shall be further described in the <220> to <223> feature section.	
<213>	Organism	Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.	M
<220>	Feature	Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<221>	Name/Key	Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence
<222>	Location	Specify location within sequence; where appropriate state number of first and last bases/amino acids	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

<223>	Other Information	Other relevant information; four lines maximum	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA
<300>	Publication Information	Leave blank after <300>	O
<301>	Authors	Preferably max of ten named authors of publication; specify one name per line; preferable format: Surname, Other Names and/or Initials	O
<302>	Title		O
<303>	Journal		O
<304>	Volume		O
<305>	Issue		O
<306>	Pages		O
<307>	Date	Journal date on which data published; specify as yyyy-mm-dd, MMM-yyyy or Season-yyyy	O
<308>	Database Accession Number	Accession number assigned by database including database name	O
<309>	Database Entry Date	Date of entry in database; specify as yyyy-mm-dd or MMM-yyyy	O
<310>	Patent Document Number	Document number; for patent-type citations only. Specify as, for example, US 07/999,999	O

<311>	Patent Filing Date	Document filing date, for patent-type citations only; specify as yyyy-mm-dd	
<312>	Publication Date	Document publication date, for patent-type citations only; specify as yyyy-mm-dd	O
<313>	Relevant Residues	FROM (position) TO (position)	O
<400>	Sequence	SEQ ID NO should follow the numeric identifier and should appear on the line preceding the actual sequence	M

5. Section 1.024 is revised to read as follows:

1.024 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.

(a) The computer readable form required by 1.021(c) shall meet the following specifications:

(1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.

(2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.

(3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.

(4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.

(5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.

(6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.

(b) Computer readable form submissions must meet these format requirements:

(1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;

(2) Operating System: MS-DOS, Unix or Macintosh;

~~   CProject   ~~

CProjectData   Novel Polypeptide
PC10970AGLK
_____-__-__   H: ~~

CDNASequence

First Sequence

Homo sapiens~r atgcctggcc acaatacctc caggaattcc tcttgcgatc ctatagtgac accccactta   60
atcagcctct acttcatagt gcttattggc gggctggtgg gtgtcatttc cattcttttc   120
ctcctggtga aaatgaacac ccggtcagtg accaccatgg cggtcattaa cttggtggtg   180
gtccacagcg tttttctgct gacagtgcca tttcgcttga cctacctcat caagaagact   240
tggatgtttg ggctgccctt ctgcaaattt gtgagtgcca tgctgcacat ccacatgtac   300
ctcacgttcc tattctatgt ggtgatcctg gtcaccagat acctcatctt cttcaagtgc   360
aaagacaaag tggaattcta cagaaaactg catgctgtgg ctgccagtgc tggcatgtgg   420
acgctggtga ttgtcattgt ggtacccctg gttgtctccc ggtatggaat ccatgaggaa   480
tacaatgagg agcactgttt taaatttcac aaagagcttg cttacacata tgtgaaaatc   540

(sample of submitted file)

I f PatentIn software was used to create
the file, please contact Robert Wax at 703-306-4119 or
703-308-4216
for assistance

RJI   Review the Sequence Listing to insure a corresponding
explanation is presented in the <220> to <223> fields of
each sequence using n or Xaa.